肺癌血管靶向治疗新进展.pptVIP

吉西他滨＋顺铂（GP）联合恩度及恩度维持治疗ⅢB/Ⅳ期非小细胞肺癌的临床研究 研究组长单位：四川大学华西医院 注册号：ChiCTR-TNC? 抗血管药物恩度使用5天后，IHC、RT-PCR、Western Blot、免疫荧光及透射电镜均显示周细胞覆盖于肿瘤内皮细胞，数量增加. 恩度使用5天后，肿瘤乏氧改善 初步结论： 恩度有肿瘤血管正常化效应 肿瘤血管正常化时间窗始于用药后第5天 动物实验结果——临床效应 临床试验 适合患者入组，恩度用药5天后才开始化疗。 利用CT成像观察血流灌注的变化 已经通过伦理审查。 1.Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The endpoints were overall survival (OS), progression-free survival (PFS) and side effects. 2.We analyzed the use of Bev in the doses of 7.5 mg/kg and 15 mg/kg. 3.The final analysis included 4 trials, comprising 2200 patients. The combination of CT plus Bev increased the response rate and progression-free survival of patients with NSCLC. With respect to overall survival the benefits of Bev remains uncertain. * * In conclusion, addition of bevacizumab to first-line CP results in similar PFS benefits in Japanese patients with advanced non-squamous NSCLC as in Western patients. No new safety concerns were raised in Japanese population. * 研究结果表明恩度可显著提高客观有效率。从图中我们可以看出。恩度组和对照组的总RR分别为35.4%和19.5%，恩度提高总RR15.9%。对初治患者,恩度组和对照组的RR分别为40.0%和23.9%，恩度提高16.1%。对复治患者,试验组和对照组的RR分别为23.9%和8.5%，恩度提高15.4%。且3项比较均有显著性差异。 * 同时恩度可显著提高中位TTP，延长患者疾病进展时间 恩度组和对照组相比延长了2.7个月的中位TTP时间。 * 从患者生存情况来看，恩度组中位OS为14.87个月，比对照组提高了4.97个月。 * * * * NP方案患者TTP为7.5个月，GP为7.86个月，TP为8.32个月，DP为5.79个月。说明恩度联合多种化疗方案均有效，且各组间无显著性差异。 * 下面我们来看下安全性方面的结果。按系统分类，各系统发生的不良事件的比例分别为。。。。，我们知道其中血液系统，消化系统的不良事件大部分和化疗相关。 * * Bevacizumab + erlotinib followed by chemotherapy at progressive disease is feasible in advanced non-squamous NSCLC with low toxicity and promising activity The OS reported here is similar to that observed with first-line chemotherapy regimens These findings raise the question as to whether BE could be used as first-line therapy for an unselected patient population with advanced non-squamous NSCLC Patients with EGFR mutations had a higher ORR and longer OS and TTP. However, overall results remain unchanged when these patients are excluded, suggesting that the addition of B